

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Lysine-specific histone demethylase 1 (LSD1)	<i>In vitro</i> studies identified tranlycypromine-derived LSD1 inhibitors that might help treat cancer. Hybrid molecules consisting of the LSD1 inhibitor tranlycypromine linked to lysine had LSD1 selectivity that was 400–11,000 times greater than that of the tranlycypromine parent compound. In human cancer cell lines, the hybrid compounds inhibited growth with GI <sub>50</sub> values of 6–67 μM. Next steps include studies in animal models of cancer.  <b>SciBX 2(47); doi:10.1038/scibx.2009.1722</b> <b>Published online Dec. 10, 2009</b>	Patent application filed; available for licensing from Nagoya City University	Ueda, R. <i>et al.</i> <i>J. Am. Chem. Soc.</i> ; published online Nov. 16, 2009; doi:10.1021/ja907055q <b>Contact:</b> Naoki Miyata, Nagoya City University, Aichi, Japan e-mail: <a href="mailto:miyata-n@phar.nagoya-cu.ac.jp">miyata-n@phar.nagoya-cu.ac.jp</a> <b>Contact:</b> Takayoshi Suzuki, same affiliation as above e-mail: <a href="mailto:suzuki@phar.nagoya-cu.ac.jp">suzuki@phar.nagoya-cu.ac.jp</a> <b>Contact:</b> Tamio Mizukami, Nagahama Institute of Bio-Science and Technology, Shiga, Japan e-mail: <a href="mailto:mizukami@nagahama-i-bio.ac.jp">mizukami@nagahama-i-bio.ac.jp</a>